XML 61 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Total Net Product Revenues Based on Patient Location (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]        
Revenue $ 408,742 $ 476,784 $ 1,396,465 $ 1,408,338
United States        
Disaggregation of Revenue [Line Items]        
Revenue 196,239 252,948 608,670 729,672
Europe        
Disaggregation of Revenue [Line Items]        
Revenue 115,497 121,158 450,016 375,453
Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 38,958 44,064 140,911 141,852
Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 58,048 58,614 196,868 161,361
Total net product revenues        
Disaggregation of Revenue [Line Items]        
Revenue 393,840 460,741 1,348,279 1,368,816
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim        
Disaggregation of Revenue [Line Items]        
Revenue 369,460 419,754 1,245,762 1,239,871
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | United States        
Disaggregation of Revenue [Line Items]        
Revenue 166,554 203,892 491,028 582,734
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Europe        
Disaggregation of Revenue [Line Items]        
Revenue 108,568 115,548 424,144 360,718
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Latin America        
Disaggregation of Revenue [Line Items]        
Revenue 38,958 44,064 140,911 141,852
Marketed by Company | Brineura, Firdapse, Kuvan, Naglazyme, Palynziq, and Vimizim | Rest of world        
Disaggregation of Revenue [Line Items]        
Revenue 55,380 56,250 189,679 154,567
Marketed by Genzyme | Aldurazyme        
Disaggregation of Revenue [Line Items]        
Revenue $ 24,380 $ 40,987 $ 102,517 $ 128,945